TM-FLOW HARDWARE

Tm-flow ANS Testing Medical Device Is a Highly Comprehensive, User-friendly, Non-invasive Tool That Focuses on Early Detection and Follow-up of Complications (Autonomic Nervous System & Vascular System) by Measuring 8 Health Risk Areas Within the Body. This ANS Testing Medical Device Effectively Measures the State of a Patient’s Health by Screening for Hidden Causes of Disease and Other Chronic Metabolic Diseases Such as Diabetes and Other Cardiometabolic Risks.

FDA Approved Medical Device

SCIENTIFICALLY VALIDATED WITH 5 FDA CLEARANCES, our Class 2
analytical medical device performs a complete patient health risk analysis.
Through the PECE Medical Device Platform, you, the physician, gain
immediate access to various highly actionable medical data on the patient.
This exam is covered and reimbursed by most insurance.

Assessment of the Autonomic Nervous System

through TM-Flow medical device

The accurate detection of the beat-to-beat heart rate (RR-intervals) is analyzed by The TM-Flow medical device scan, through the Photoplethysmography (PTG) waveform.

While lying and standing, the blood pressure is measured by oscillometry (TM-Flow) or by volume plethysmography.

The sudomotor function is assessed by a galvanic skin response device either using metal plates following the electrical stimulation of the sweat glands (ANS-1) or disposable cloth electrodes and pressure cuffs placed on the ankles following a double stimulation - the metaboreflex and the electrical stimulation of the sweat glands (TM-Flow).

THE TM-FLOW MEDICAL DEVICE OVERVIEW

Our TM-Flow ANS testing platform is a Medical Device Data System that uses all four LD Technologies to
identify the different Markers that demonstrate the Patient Health Conditions.

ASSESSMENTS

Cardiac Autonomic Neuropathy

Sudomotor

Endothelial Dysfunction

Ankle brachial Indices

Lifestyle

Cardiometabolic Risk Score

HOW

Guidelines of the CAN Subcommittee of the Toronto Consensus Panel Statement

The Patented sequence of electrical stimulation measured at negative and positive electrodes

The Patented analysis of the PTG spectral analysis and vasomotion

Synchronization of 4 Bluetooth BP devices and Heart association guidance.

Fat Mass by BIA Vital signs and HRV markets

Based on Abnormal results of all the CMAT markers

WHY? CLINICAL OUTCOMES

CAN is a high-risk factor of CVD
and hypoglycemia (Hb1Ac target)

Early detection of Small fiber Neuropathy and adapted treatment options.

Insulin resistance Inflammation Thrombotic risk Vasodilation responses Blood flow

Early detection of Peripheral artery disease and treatment options

Visualization and evaluation of the lifestyle changes

Treatment follow up and early detection of
micro and/or macrovasdcular complications.

The TM-Flow System Markers

THE MARKERS FOR THE TM-FLOW SYSTEM INCLUDE:

ANS ASSESSMENT MARKERS

SUDOMOTOR MARKERS

CARDIAC AUTONOMIC REFLEX TESTS (CARTS)

HEART RATE VARIABILITY (HRV)

VASCULAR ASSESSMENT MARKERS

PERIPHERAL CIRCULATION MARKERS

SEGMENTAL VASCULAR ASSESSMENT

ADDITIONAL MARKER

LIFESTYLE MARKER

Integrated Different Technologies in the

TM Flow Medical Device

The assessment of the Autonomic Nervous System and Vascular system requires several different diagnostic tools, which may be expensive and time-consuming; our TM-Flow device, with its advanced technology, helps physicians to detect ANS and Vascular function through only one exam. Moreover, the integration of these different technologies reduces the time to perform the other measurements.

Sometimes it is difficult for Physicians to differentiate vascular from neuropathic disorders. TM-Flow will help the physician to distinguish between autonomic neuropathy and vascular dysfunction symptoms. As a result, TM-Flow offers physicians a better tool for early detection of chronic disease and more treatment options.

Uses of TM-Flow Medical Device in

a Clinical Setting

This device aims to provide physicians with new technology and a better approach to detect and treat Diabetes and its complications. Diabetes damages the autonomic nerves and micro/macrovascular systems.

Unfortunately, the current laboratory system fails to provide effective treatment results for the early detection of diabetes and its complications. Our ANS device platform offers a better solution to improve a patient’s health conditions.